Alpha Teknova, Inc. TKNO
Alpha Teknova, Inc. (referred to herein as the Company, Teknova, we, us or our) is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our more than 3,000 customers span the continuum of the life sciences market and include leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our Company is built around our knowledge, methods, and know-how in our manufacturing processes and infrastructure, which are highly adaptable and configurable. These proprietary processes enable us to manufacture and deliver high-quality, custom, made-to-order products with short turnaround times and at scale, across all stages of our customers' product development, including commercialization.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $40.5M | $37.7M | $36.7M | $41.4M | $36.9M | $31.3M | — |
| Cost of revenue | $27.1M | $30.5M | $26.4M | $23.9M | $19.3M | $13.5M | — |
| Gross profit | $13.4M | $7.2M | $10.3M | $17.5M | $17.6M | $17.8M | — |
| R&D | $2.2M | $2.8M | $5.6M | $7.7M | $4.3M | $1.5M | — |
| SG&A | $20.3M | $23.1M | $25.4M | $28.3M | $20.4M | $8.2M | — |
| Total operating expenses | $30.4M | $33.4M | $45.9M | $67.1M | $29.6M | $13.1M | — |
| Operating income | -$17.0M | -$26.1M | -$35.6M | -$49.7M | -$12.0M | $4.7M | — |
| Interest expense | $710.0K | $687.0K | $833.0K | $213.0K | $589.0K | $87.0K | — |
| Pre-tax income | -$17.2M | -$26.8M | -$37.1M | -$49.4M | -$12.6M | $4.7M | — |
| Income tax | $58.0K | $88.0K | $298.0K | $1.9M | $2.8M | $1.2M | — |
| Net income | -$17.3M | -$26.7M | -$36.8M | -$47.5M | -$9.8M | $3.6M | — |
| EPS, basic | -0.32 | -0.57 | -1.16 | -1.69 | -0.61 | 0.17 | — |
| EPS, diluted | -0.32 | -0.57 | -1.16 | -1.69 | -0.61 | 0.16 | — |
| Shares, diluted (wtd. avg.) | $53.5M | $46.7M | $31.8M | $28.1M | $16.1M | $3.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.9M | $3.7M | $28.5M | $42.2M | $87.5M | $3.3M | $4.1M |
| Short-term investments | $15.4M | $26.7M | $0 | — | $0 | $1.8M | — |
| Receivables | $4.6M | $4.3M | $3.9M | $4.3M | $4.7M | $4.6M | — |
| Inventory | $7.1M | $6.8M | $11.6M | $12.2M | $5.4M | $3.6M | — |
| Total current assets | $34.5M | $42.8M | $45.7M | $61.1M | $101.2M | $16.4M | — |
| Property, plant and equipment | $41.7M | $45.8M | $50.4M | $51.6M | $29.8M | $10.0M | — |
| Goodwill | — | — | — | $0 | $16.6M | $16.6M | — |
| Other intangibles | $11.9M | $13.1M | $14.2M | $17.6M | $18.7M | $19.9M | — |
| Total assets | $103.6M | $118.8M | $128.6M | $152.3M | $166.5M | $62.9M | — |
| Accounts payable | $1.4M | $825.0K | $1.5M | $2.4M | $2.2M | $1.6M | — |
| Short-term debt | $0 | $4.0M | $0 | — | — | — | — |
| Total current liabilities | $7.5M | $11.2M | $8.9M | $10.9M | $7.7M | $4.0M | — |
| Long-term debt | $13.1M | $9.4M | $13.3M | $22.0M | $11.9M | $0 | — |
| Total liabilities | $34.8M | $36.4M | $38.6M | $52.4M | $23.3M | $10.5M | — |
| Retained earnings | -$135.8M | -$118.5M | -$91.8M | -$55.0M | -$7.5M | $2.3M | — |
| Total equity | $68.8M | $82.4M | $90.0M | $99.9M | $143.2M | $16.8M | $12.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.6M | -$12.4M | -$18.8M | -$27.4M | -$9.1M | $2.5M | — |
| Depreciation and amortisation | $6.3M | $6.6M | $5.7M | $4.5M | $2.9M | $2.0M | — |
| Stock-based compensation | $3.4M | $3.7M | $4.1M | $3.7M | $1.6M | $300.0K | — |
| Capital expenditure | $1.1M | $1.1M | $7.9M | $28.1M | $19.9M | $5.5M | — |
| Investing cash flow | $10.7M | -$27.3M | -$7.7M | -$28.1M | -$17.5M | -$1.7M | — |
| Financing cash flow | $151.0K | $14.9M | $12.8M | $10.3M | $110.8M | -$1.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001850902-26-000002.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $42.18B | 40.9x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.59B | 29.6x | 0.5% |
| CLDX | Celldex Therapeutics, Inc. | $3.12B | — | -78.0% |
| NEOG | NEOGEN CORP | $2.58B | — | -2.7% |
| NTLA | Intellia Therapeutics, Inc. | $1.79B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $958.0M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $873.6M | — | — |
| MYGN | MYRIAD GENETICS INC | $305.1M | — | -1.6% |